{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T10:44:51Z","timestamp":1774608291911,"version":"3.50.1"},"reference-count":47,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,2,25]],"date-time":"2013-02-25T00:00:00Z","timestamp":1361750400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2013,2,25]],"date-time":"2013-02-25T00:00:00Z","timestamp":1361750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Blood Cancer"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1002\/pbc.24498","type":"journal-article","created":{"date-parts":[[2013,2,25]],"date-time":"2013-02-25T17:13:02Z","timestamp":1361812382000},"page":"1528-1533","source":"Crossref","is-referenced-by-count":30,"title":["Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: A north American perspective"],"prefix":"10.1002","volume":"60","author":[{"given":"Etan","family":"Orgel","sequence":"first","affiliation":[{"name":"Jonathan Jaques Children's Cancer Center; Miller Children's Hospital; Long Beach, California"},{"name":"Department of Pediatrics; Keck School of Medicine, University of Southern California; Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Zung","sequence":"additional","affiliation":[{"name":"LIFE Cancer Survivorship & Transition Program; Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles; Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyun","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine; Keck School of Medicine\/USC Norris Comprehensive Cancer Center; Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Finklestein","sequence":"additional","affiliation":[{"name":"Jonathan Jaques Children's Cancer Center; Miller Children's Hospital; Long Beach, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Feusner","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology; Children's Hospital and Research Center; Oakland, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Freyer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; Keck School of Medicine, University of Southern California; Los Angeles, California"},{"name":"LIFE Cancer Survivorship & Transition Program; Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles; Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,2,25]]},"reference":[{"key":"10.1002\/pbc.24498-BIB0001|pbc24498-cit-0001","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/jnci\/djn276","article-title":"Trends in 5-and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004","volume":"100","author":"Pulte","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1002\/pbc.24498-BIB0002|pbc24498-cit-0002","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1200\/JCO.2009.27.0421","article-title":"Outcomes for children and adolescents with cancer: Challenges for the twenty-first century","volume":"28","author":"Smith","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24498-BIB0003|pbc24498-cit-0003","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1038\/sj.leu.2403924","article-title":"Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials","volume":"19","author":"Gibson","year":"2005","journal-title":"Leukemia"},{"key":"10.1002\/pbc.24498-BIB0004|pbc24498-cit-0004","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1200\/JCO.2004.11.106","article-title":"Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of Cancer and Leukemia Group B Study 962","volume":"22","author":"Kolitz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24498-BIB0005|pbc24498-cit-0005","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1002\/pbc.24498-BIB0006|pbc24498-cit-0006","unstructured":"National Cancer Institute Clinical Trials Database: Phase II\/III Randomized Study of Bortezomib and Sorafenib Tosylate in Patients With De Novo Acute Myeloid Leukemia With or Without High Allelic Ratio FLT3\/ITD Mutations http:\/\/cancer.gov\/clinicaltrials\/COG-AAML 1031"},{"key":"10.1002\/pbc.24498-BIB0007|pbc24498-cit-0007","unstructured":"National Cancer Institute Clinical Trials Database: Phase III Randomized Study of Conventional Combination Chemotherapy With Versus Without Gemtuzumab Ozogamicin in Young Patients With Newly Diagnosed Acute Myeloid Leukemia http:\/\/cancer.gov\/clinicaltrials\/COG-AAML 0531"},{"key":"10.1002\/pbc.24498-BIB0008|pbc24498-cit-0008","unstructured":"National Institute of Health Clinical Trials Database: Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia http:\/\/clinicaltrials.gov\/show\/NCT 00703820"},{"key":"10.1002\/pbc.24498-BIB0009|pbc24498-cit-0009","doi-asserted-by":"crossref","first-page":"b4606","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ"},{"key":"10.1002\/pbc.24498-BIB0010|pbc24498-cit-0010","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ejca.2011.05.023","article-title":"Systolic and diastolic dysfunction in long-term adult survivors of childhood cancer","volume":"47","author":"Brouwer","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1002\/pbc.24498-BIB0011|pbc24498-cit-0011","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12012-007-0006-4","article-title":"Anthracycline cardiotoxicity in long-term survivors of childhood cancer","volume":"7","author":"Scully","year":"2007","journal-title":"Cardiovasc Toxicol"},{"key":"10.1002\/pbc.24498-BIB0012|pbc24498-cit-0012","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/pbc.20352","article-title":"Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: Implications for screening and prevention","volume":"44","author":"Adams","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24498-BIB0013|pbc24498-cit-0013","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminoncol.2006.04.020","article-title":"Pathogenesis of cardiotoxicity induced by anthracyclines","volume":"33","author":"Elliott","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1002\/pbc.24498-BIB0014|pbc24498-cit-0014","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2001.19.1.191","article-title":"Anthracycline-induced clinical heart failure in a cohort of 607 children: Long-term follow-up study","volume":"19","author":"Kremer","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24498-BIB0015|pbc24498-cit-0015","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MCC.0b013e3283307a4e","article-title":"Cardiac dysfunction in severe sepsis and septic shock","volume":"15","author":"Zanotti-Cavazzoni","year":"2009","journal-title":"Curr Opin Crit Care"},{"key":"10.1002\/pbc.24498-BIB0016|pbc24498-cit-0016","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/pbc.22989","article-title":"Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors","volume":"57","author":"Abosoudah","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24498-BIB0017|pbc24498-cit-0017","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/hrt.2010.194118","article-title":"Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy","volume":"96","author":"Cheung","year":"2010","journal-title":"Heart"},{"key":"10.1002\/pbc.24498-BIB0018|pbc24498-cit-0018","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/pbc.21100","article-title":"B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children","volume":"49","author":"Aggarwal","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24498-BIB0019|pbc24498-cit-0019","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa035153","article-title":"The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia","volume":"351","author":"Lipshultz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1002\/pbc.24498-BIB0020|pbc24498-cit-0020","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1200\/JCO.2010.30.3404","article-title":"Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: Associations with long-term echocardiographic outcomes","volume":"30","author":"Lipshultz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24498-BIB0021|pbc24498-cit-0021","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1200\/JCO.2007.14.9401","article-title":"Anthracycline cardiotoxicity: From bench to bedside","volume":"26","author":"Gianni","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24498-BIB0022|pbc24498-cit-0022","unstructured":"National Cancer Institute Clinical Trials Database: Phase II Pilot Study of Gemtuzumab Ozogamicin in Children With Newly Diagnosed Acute Myeloid Leukemia Undergoing Intensive Remission Induction and Intensification Therapy http:\/\/cancer.gov\/clinicaltrials\/COG-AAML03P1"},{"key":"10.1002\/pbc.24498-BIB0023|pbc24498-cit-0023","unstructured":"National Cancer Institute Clinical Trials Database: Phase III Randomized Study of Conventional Combination Chemotherapy With Versus Without Gemtuzumab Ozogamicin in Young Patients With Newly Diagnosed Acute Myeloid Leukemia http:\/\/cancer.gov\/clinicaltrials\/COG-AAML 0531"},{"key":"10.1002\/pbc.24498-BIB0024|pbc24498-cit-0024","volume-title":"Holland-Frei cancer medicine","author":"Ewer","year":"2003"},{"key":"10.1002\/pbc.24498-BIB0025|pbc24498-cit-0025","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2141.1998.00948.x","article-title":"A systemic collaborative overview of randomized trials comparing idarubicin with daunorubicn (or other anthracyclines) as induction therapy for acute myeloid leukaemia","volume":"103","author":"The AML Collaborative Group","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1002\/pbc.24498-BIB0026|pbc24498-cit-0026","volume-title":"CDC growth charts: United States. Advance data from vital and health statistics","volume":"314","author":"Kuczmarski","year":"2000"},{"key":"10.1002\/pbc.24498-BIB0027|pbc24498-cit-0027","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/pbc.22908","article-title":"Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: Retrospective cohort study in a single centre in the United Kingdom","volume":"56","author":"Temming","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24498-BIB0028|pbc24498-cit-0028","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/pbc.21105","article-title":"Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML","volume":"48","author":"Creutzig","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24498-BIB0029|pbc24498-cit-0029","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1200\/JCO.2002.20.6.1677","article-title":"Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol","volume":"20","author":"Lipshultz","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24498-BIB0030|pbc24498-cit-0030","volume-title":"Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, Version 3.0","author":"Children's Oncology Group","year":"2008"},{"key":"10.1002\/pbc.24498-BIB0031|pbc24498-cit-0031","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2010.33.7907","article-title":"Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy","volume":"30","author":"Lipshultz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24498-BIB0032|pbc24498-cit-0032","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.2011.40.3584","article-title":"Screening adult survivors of childhood cancer for cardiomyopathy: Comparison of echocardiography and cardiac magnetic resonance imaging","volume":"30","author":"Armstrong","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24498-BIB0033|pbc24498-cit-0033","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1002\/pbc.24498-BIB0034|pbc24498-cit-0034","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1161\/CIRCIMAGING.112.977751","article-title":"Screening for long-term cardiac status during cancer treatment","volume":"5","author":"Lipshultz","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1002\/pbc.24498-BIB0035|pbc24498-cit-0035","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1200\/JCO.1986.4.6.918","article-title":"Amsacrine-associated cardiotoxicity: An analysis of 82 cases","volume":"4","author":"Weiss","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24498-BIB0036|pbc24498-cit-0036","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.1997.15.4.1544","article-title":"Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group cxperience","volume":"15","author":"Krischer","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24498-BIB0037|pbc24498-cit-0037","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes-A report from the Children's Oncology Group","volume":"30","author":"Blanco","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24498-BIB0038|pbc24498-cit-0038","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1200\/JCO.1988.6.8.1321","article-title":"Doxorubicin clearance in the obese","volume":"6","author":"Rodvold","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24498-BIB0039|pbc24498-cit-0039","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/jama.293.2.203","article-title":"Mortality in overweight and underweight children with acute myeloid leukemia","volume":"293","author":"Lange","year":"2005","journal-title":"JAMA"},{"key":"10.1002\/pbc.24498-BIB0040|pbc24498-cit-0040","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.3574.3574","article-title":"Extremes of weight are associated with increased treatment-related toxicity in high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group","volume":"118","author":"Orgel","year":"2011","journal-title":"Blood"},{"key":"10.1002\/pbc.24498-BIB0041|pbc24498-cit-0041","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","article-title":"Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease","volume":"25","author":"Tebbi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24498-BIB0042|pbc24498-cit-0042","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2007.12.2481","article-title":"Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane","volume":"26","author":"Barry","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24498-BIB0043|pbc24498-cit-0043","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","article-title":"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial","volume":"11","author":"Lipshultz","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1002\/pbc.24498-BIB0044|pbc24498-cit-0044","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1470-2045(10)70301-6","article-title":"Should anthracyclines and dexrazoxane be used for children with cancer","volume":"12","author":"van Dalen","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1002\/pbc.24498-BIB0045|pbc24498-cit-0045","first-page":"CD005006","article-title":"Different anthracycline derivates for reducing cardiotoxicity in cancer patients","volume":"5","author":"van Dalen","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1002\/pbc.24498-BIB0046|pbc24498-cit-0046","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/cncr.20207","article-title":"Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin","volume":"100","author":"Theodoulou","year":"2004","journal-title":"Cancer"},{"key":"10.1002\/pbc.24498-BIB0047|pbc24498-cit-0047","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/10428190500052438","article-title":"The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia","volume":"46","author":"Fassas","year":"2005","journal-title":"Leuk Lymphoma"}],"container-title":["Pediatric Blood & Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24498","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24498","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/pbc.24498\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T10:39:50Z","timestamp":1596105590000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/pbc.24498"}},"subtitle":["Early Cardiac Outcomes After Pediatric AML"],"short-title":[],"issued":{"date-parts":[[2013,2,25]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"URL":"https:\/\/doi.org\/10.1002\/pbc.24498","archive":["Portico"],"relation":{},"ISSN":["1545-5009"],"issn-type":[{"value":"1545-5009","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2,25]]}}}